Cipla News and Updates

Name: Latest research reports of Cipla Ltd. authored by Deven Choksey and published by - Trendlyne research reports.
Item: Cipla Ltd.
Rating: 4
Author: Deven Choksey

Keep track of all breaking news on Cipla from all sources in a single place.

Cipla Ltd.

04 Sep 2026

1358.00

0.52%

Cipla slips after Qilu Pembrolizumab deal; Morgan Stanley flags crowded field

Business Line

Cipla stock trades at 1,388, down 0.48% or 6.70 from its previous close of 1,394.70

Cipla Ltd. is trading below all available SMAs

Cipla Ltd.

04 Sep 2026

1358.00

0.52%

Cipla partners with Qilu to license, supply Keytruda biosimilar in US

Business Standard

Drug major Cipla Ltd on Thursday said its wholly owned subsidiary, Invagen Pharmaceuticals Inc, has entered into a strategic partnership with Qilu Pharmaceutical for the licensing and supply of a biosimilar to the cancer drug Keytruda in the United States. The product, QL2107, is a biosimilar to pembrolizumab (Keytruda) and aims to improve access to advanced therapies for cancer patients while lowering treatment costs, Cipla said in a regulatory filing. Under the agreement, Qilu will be responsible for the development, regulatory registration, and supply of the product, while Cipla will leverage its commercial presence to market the asset in the US. "This partnership reflects Cipla's confidence in the long-term potential of biosimilars and supports our strategy to build a strong oncology-focused portfolio," said Achin Gupta, Managing Director and Global Chief Executive Officer, Cipla. Hanchang Zhang, General Manager of Qilu Pharmaceutical, said, "We are pleased to establish this ..

Number of FII/FPI investors decreased from 964 to 917 in Jun 2026 qtr

Cipla's US subsidiary partners with Qilu for Keytruda biosimilar

Business Line | 04 Sep 2026

Cipla Ltd.

29 Aug 2026

1358.00

0.52%

Maharashtra FDA cancels Cipla's Pune unit licence; company contests order

Business Line

The drugmaker said the order does not allege concerns over product safety, quality or efficacy, or indicate any patient safety issue

Cipla Ltd. has an average target of 1527.75 from 8 brokers.

Maharashtra FDA cancels Cipla C&F licences in Pune; firm contests order

Business Standard | 28 Aug 2026

Cipla Ltd.

07 Aug 2026

1358.00

0.52%

Cipla Health's new 'W.H.O. hai toh woh ORS hai' campaign highlights the importance of knowing the correct ORS

Business Line

Cipla Health's new 'W.H.O. hai toh woh ORS hai' campaign highlights the importance of knowing the correct ORS

Cipla Ltd. has an average target of 1527.75 from 8 brokers.

Cipla Ltd.

05 Aug 2026

1358.00

0.52%

Karnataka attracts fresh investments from Cipla, Rocket India during Mumbai roadshow

Business Line

Karnataka's investment outreach gained momentum with major manufacturing expansion plans and fresh investor interest across infrastructure, renewable energy and industries.

Cipla Ltd. is trading below all available SMAs

Cipla Ltd.

30 Jul 2026

1358.00

0.52%

Cipla Health's new 'W.H.O. hai toh woh ORS hai' campaign highlights the importance of knowing the correct ORS

Business Line

Cipla Health's new 'W.H.O. hai toh woh ORS hai' campaign highlights the importance of knowing the correct ORS

Number of FII/FPI investors decreased from 964 to 917 in Jun 2026 qtr

Cipla Ltd.

27 Jul 2026

1358.00

0.52%

Outlook

Accumulate: Cipla Ltd.

Target

Deven Choksey

We expect Cipla to deliver sustainable long-term growth, supported by the continued strength of its India formulations business, an improving chronic therapy mix, and a robust branded franchise.

Cipla Ltd. has an average target of 1527.75 from 8 brokers.

Cipla Ltd.

24 Jul 2026

1358.00

0.52%

Cipla shares rise 3.5% after Q1; brokerages cautious, trim target

Business Standard

Cipla reported a 39.2 per cent fall in net profit for the first quarter to 789.05 crore on a year-on-year basis. Revenue for the quarter was up at 7,119.28 crore

Number of FII/FPI investors decreased from 964 to 917 in Jun 2026 qtr

Cipla shares rise 3.7% despite Q1 profit fall, brokerages remain cautious

Business Line | 24 Jul 2026 4 more

Cipla Ltd.

24 Jul 2026

1358.00

0.52%

Cipla Ltd.

Buy: Cipla Ltd.

Target

ICICI Direct

grew just 3.5% YoY to 7077 crore mainly on the back of weak North America Business which de-grew 21% to 1532 crore. The weakness was on account of high base of gRevlimid and absence of anti-growth hormone drug Lanreotide. On the other hand, domestic formulations (One India) grew 12.4% to 3452 crore, Africa grew 12% to 977 crore, and RoW market grew 27% to 1317 crore. EBITDA de-grew ~33% YoY to 1192 crore with EBITDA margins of 16.7% down 881 bps; GPM declined by 626 bps and stood at 62.5%. PAT de-grew 39% to 786 crore....